



# NGL Fine-Chem Limited

Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India.  
Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: [info@nglfinechem.com](mailto:info@nglfinechem.com) CIN L24110MH1981PLC025884, Website [www.nglfinechem.com](http://www.nglfinechem.com)

August 12, 2024

To,  
Listing Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai — 400 001.  
Scrip Code: 524774

To,  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No.C/1, G Block,  
Bandra Kurla Complex, Bandra East,  
Mumbai 400050.  
Symbol: NGLFINE

**Sub: Outcome of the Board Meeting Dated 12<sup>th</sup> August, 2024.**

Dear Sir/Madam,

This is to inform you that the second Meeting of the Board of Directors of NGL Fine-Chem Limited for the Financial Year 2024-2025 held on Monday, 12<sup>th</sup> August, 2024 at 301 E-Square, Subhash Road, Vile Parle East, Mumbai 400057 approved the Unaudited Standalone & Consolidated Financial Results for the quarter ended 30<sup>th</sup> June, 2024 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review Report issued by the Statutory Auditors of the Company.

The aforesaid results are also being disseminated on Company's website at [www.nglfinechem.com](http://www.nglfinechem.com).

The meeting of the Board of Directors commenced at 5.30 p.m. and concluded at 6.45 p.m.

Kindly take the same on your record.

Thanking you,

Yours faithfully,  
For NGL Fine-Chem Limited

**Pallavi Satish Pednekar**  
Digitally signed by  
Pallavi Satish Pednekar  
Date: 2024.08.12  
18:49:22 +05'30'

Pallavi Pednekar  
Company Secretary & Compliance Officer  
Membership No: A33498

# NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road, Vile Parle ( East), Mumbai 400 057, Maharashtra, India.

CIN: L24110MH1981PLC025884



UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2024

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2024

Particulars		Rupees in lakhs				Particulars		Rupees in lakhs			
		Quarter ended		Year ended				Quarter ended		Year ended	
		30.06.2024 (Unaudited)	31.03.2024 (Audited)	30.06.2023 (Unaudited)	31.03.2024 (Audited)			30.06.2024 (Unaudited)	31.03.2024 (Audited)	30.06.2023 (Unaudited)	31.03.2024 (Audited)
I	Revenue from Operations	9,075.35	9,976.09	7,104.21	33,868.84	I	Revenue from Operations	8,803.44	9,560.86	6,911.35	32,897.29
II	Other Income	588.46	368.02	332.16	1,412.80	II	Other Income	626.66	416.40	380.23	1,590.14
III	<b>Total Revenue (I+II)</b>	<b>9,663.81</b>	<b>10,344.11</b>	<b>7,436.37</b>	<b>35,281.64</b>	III	<b>Total Revenue (I+II)</b>	<b>9,430.10</b>	<b>9,977.26</b>	<b>7,291.58</b>	<b>34,487.43</b>
IV	Expenses :					IV	Expenses :				
	a) Cost of Material Consumed	4,154.52	5,177.52	3,247.76	17,081.19		a) Cost of Material Consumed	4,042.49	5,001.40	3,153.70	16,658.42
	b) (Increase)/Decrease in stock in trade and work in progress	562.69	(446.93)	144.89	(1,212.51)		b) (Increase)/Decrease in stock in trade and work in progress	591.48	(452.29)	165.38	(1,205.83)
	c) Employee benefits expenses	1,191.70	1,209.44	1,060.87	4,511.63		c) Employee benefits expenses	1,084.84	1,095.03	979.39	4,132.49
	d) Finance Costs	44.34	48.79	24.29	133.81		d) Finance Costs	44.34	45.80	24.29	133.81
	e) Depreciation and amortisation expenses	300.46	292.02	285.85	1,164.18		e) Depreciation and amortisation expenses	214.04	206.45	199.89	814.79
	f) Other expenses	2,231.40	2,453.86	1,664.31	8,161.64		f) Other expenses	2,452.75	2,657.15	1,852.83	8,882.92
	<b>Total Expenses (IV)</b>	<b>8,485.11</b>	<b>8,734.70</b>	<b>6,427.97</b>	<b>29,839.94</b>		<b>Total Expenses (IV)</b>	<b>8,429.94</b>	<b>8,553.54</b>	<b>6,375.48</b>	<b>29,416.60</b>
V	Profit/(loss) before exceptional items and tax (III-IV)	1,178.70	1,609.41	1,008.40	5,441.70	V	Profit/(loss) before exceptional items and tax (III-IV)	1,000.16	1,423.72	916.10	5,070.83
VI	Exceptional Items	-	-	-	-	VI	Exceptional Items	-	-	-	-
VII	<b>Profit/(loss) Before Tax (V-VI)</b>	<b>1,178.70</b>	<b>1,609.41</b>	<b>1,008.40</b>	<b>5,441.70</b>	VII	<b>Profit/(loss) Before Tax (V-VI)</b>	<b>1,000.16</b>	<b>1,423.72</b>	<b>916.10</b>	<b>5,070.83</b>
VIII	Tax Expense					VIII	Tax Expense				
	a) Current Tax	(222.50)	(361.50)	(205.00)	(1,182.50)		a) Current Tax	(182.50)	(327.50)	(186.00)	(1,112.50)
	b) MAT Tax	-	0	-	-		b) MAT Tax	-	-	-	-
	c) Prior Years	-	0	67.62	(40.00)		c) Prior Years	-	-	67.62	(28.83)
	d) Deferred Tax	(34.29)	(15.44)	(20.33)	(87.53)		c) Deferred Tax	(35.09)	(11.34)	(17.16)	(77.56)
IX	<b>Profit/ (Loss) for the period from continuing operations (VII-VIII)</b>	<b>921.91</b>	<b>1,232.47</b>	<b>850.69</b>	<b>4,131.67</b>	IX	<b>Profit/ (Loss) for the period from continuing operations (VII-VIII)</b>	<b>782.57</b>	<b>1,084.88</b>	<b>780.56</b>	<b>3,851.94</b>
X	Other Comprehensive Income					X	Other Comprehensive Income				
	a. Gain/(Loss) on actuarial valuation of post employment benefits	0.11	0.67	(31.28)	(20.42)		a. Gain/(Loss) on actuarial valuation of post employment benefits	0.44	(0.21)	(30.95)	(20.47)
	b. Deferred tax on above	(0.02)	0.17	7.88	5.14		b. Deferred tax on above	(0.11)	0.05	7.79	5.15
	c. Other Comprehensive Income (Net of Tax)	0.87	(0.50)	(23.40)	(15.28)		c. Other Comprehensive Income (Net of Tax)	0.33	(0.16)	(23.16)	(15.32)
XI	<b>Total Comprehensive Income</b>	<b>922.78</b>	<b>1,231.97</b>	<b>827.29</b>	<b>4,116.39</b>	XI	<b>Total Comprehensive Income</b>	<b>782.90</b>	<b>1,084.72</b>	<b>757.40</b>	<b>3,836.62</b>
XII	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90	XII	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90
XXIII	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A	25,971.64	XXIII	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A	25,971.64
XIV	Earnings Per Share (EPS)					XIV	Earnings Per Share (EPS)				
	a) Basic	₹ 14.92	₹ 19.95	₹ 13.77	₹ 66.88		a) Basic	₹ 12.67	₹ 17.56	₹ 12.63	₹ 62.35
	b) Diluted	₹ 14.92	₹ 19.95	₹ 13.77	₹ 66.88		b) Diluted	₹ 12.67	₹ 17.56	₹ 12.63	₹ 62.35

**Notes:**

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Monday, 12th August 2024. These results were subjected to Limited Review by the Statutory Auditors of the Company.
- The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (IndAS prescribed under Section 133 of the Companies Act 2013 and read with the rules framed thereunder) and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended from time to time
- The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- The consolidated results are for NGL Fine Chem Limited together with its 100% subsidiary Macrotech Polychem Private Limited.
- The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full year ended March 31, 2024 and the published year to date figures upto the the third quarter ended December 31, 2023 of the relevant financial year
- Previous period figures have been regrouped/rearranged wherever necessary.

Place: Mumbai  
Date: 12th August 2024

**Notes:**

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Wednesday, 12th August 2024. These results were subjected to Limited Review by the Statutory Auditors of the Company.
- The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (IndAS prescribed under Section 133 of the Companies Act 2013 and read with the rules framed thereunder) and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended from time to time
- The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- Previous period figures have been regrouped/rearranged wherever necessary.
- The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full year ended March 31, 2024 and the published year to date figures upto the the third quarter ended December 31, 2023 of the relevant financial year
- Previous period figures have been regrouped/rearranged wherever necessary.

For and On behalf of Board of Directors  
  
Rajesh Lawande  
Executive Director  
DIN 00327301



# MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

A-102, Universal Paradise, Nanda Parkar Road, Vile Parle (East), Mumbai - 400 057.

Offi. # 4600 7525

# 2618 5110

shailesh.manek@gmail.com

shailesh@camanek.com

www.camanek.com

**SHAILESH MANEK**

B.Com.(Hons), Grad. C.W.A.,F.C.A.

Cell: +91 93222 26311

**MITTUL B. DALAL**

B.Com. A.C.A

Cell: +91 80973 74277

Review report to  
The Board of Directors,  
**M/s.NGL Fine-Chem Limited**

We have reviewed the accompanying statement of unaudited financial results of **M/s.NGL Fine-Chem Limited** for the period ended **June 30, 2024**.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MANEK AND ASSOCIATES**

**Chartered Accountants**

Firm's Registration No.:126679W



*M B Dalal*

**(MITTUL DALAL)**

Partner

Membership Number:172676

UDIN: **24172676BKARJI4709**

MUMBAI

Dated:12<sup>th</sup> August ,2024





# MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

A-102, Universal Paradise, Nanda Parkar Road, Vile Parle (East), Mumbai - 400 057.

Offi. # 4600 7525

# 2618 5110

shailesh.manek@gmail.com

shailesh@camanek.com

www.camanek.com

**SHAILESH MANEK**

B.Com.(Hons), Grad. C.W.A.,F.C.A.

Cell: +91 93222 26311

**MITTUL B. DALAL**

B.Com. A.C.A

Cell: +91 80973 74277

## Independent Auditor's Review Report

To,  
The Board of Directors,  
**M/s.NGL Fine-Chem Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **M/s.NGL Fine-Chem Limited** ("the Parent") and its subsidiary **M/s.Macrotech Polychem Private Limited** (the Parent and its subsidiary together referred to as "the Group", and its share of the net profit/loss) after tax and total comprehensive income/loss of its associates and joint ventures for the quarter ended **June 30, 2024** and for the period from **01<sup>st</sup> April 2024** to **30<sup>th</sup> June 2024** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

# MANEK & ASSOCIATES

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of M/s.Macrotech Polychem Private Limited, its wholly owned subsidiary.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MANEK & ASSOCIATES**  
**Chartered Accountants**  
Firm's Registration No.:**126679W**



MUMBAI  
Dated : **12<sup>th</sup> August, 2024**

*NB Dalal*

**(MITTUL DALAL)**  
Partner  
Membership Number:**172676**  
UDIN: **24172676BKARJJ9663**